Does Palliative Chemotherapy Palliate? Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1063012

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Clinical trials for women with recurrent ovarian cancer traditionally use a reduction in tumour size and time to progression to measure the benefit of chemotherapy, but do not document whether women have symptom improvement as well. The aim of the Symptom Benefit Study is to validate an instrument that will allow patients to report their symptoms and degree of improvement and for the first time allow clinical trials to include a measure of symptom improvement when new drugs are being tested.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $405,024.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology and Carcinogenesis not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chemotherapy treatment effects | ovarian cancer | palliative care | palliative treatment | quality of life

Related Links